New drug combo trial offers hope for Tough-to-Treat breast cancer
NCT ID NCT05445908
Summary
This study is testing two experimental drug combinations for people with advanced HER2-negative breast cancer that cannot be removed by surgery. Researchers want to see if adding a second drug (KL-A167) to the main treatment (SKB264) works better than using SKB264 alone. The trial will enroll 175 adults who haven't received prior drug treatment for their advanced cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER AND HR+/HER2- BC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, 410031, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
Conditions
Explore the condition pages connected to this study.